Acrivon Therapeutics, Inc. Annual Report - How They Did This Year

Hey there! Thinking about Acrivon Therapeutics (ACRV)? Let's break down their past year, which ended December 31, 2025. We'll see what it might mean for you as an investor. My goal is to make this super easy to understand. No fancy finance talk here, just the important stuff.

What Acrivon Therapeutics Actually Does

Acrivon Therapeutics is a biotech company. They discover and develop new medicines. They are "clinical-stage," meaning their potential medicines are tested in people. They are not yet approved for sale.

Their main goal is to develop drugs like ACR-368 and ACR-2316. ACR-368, also called prexasertib, blocks key proteins (CHK1 and CHK2). These proteins help cells repair damaged DNA. It is now in a Phase 2 clinical trial. This study, called APPO, treats patients with platinum-resistant ovarian cancer and other solid tumors. Their special AP3 platform identifies these tumors. ACR-2316 blocks WEE1, another important protein in DNA repair. It is currently in a Phase 1 clinical trial for patients with advanced solid tumors.

They use a special technology called "Acrivon Predictive Precision Proteomics" (AP3). This helps them find and develop drugs more effectively. Think of AP3 as their unique way to find which patients will benefit most. It identifies specific protein markers in tumors. These markers show problems with DNA repair. This helps them pick patients more likely to respond to their DNA repair-targeting treatments. The goal is to boost trial success and improve patient outcomes.

They are based in Watertown, Massachusetts. Their stock trades on the Nasdaq Global Market under ACRV.

How Their Money Situation Looks

This past year (2025), Acrivon spent a lot on research and development. Many young biotech companies do this. They have lost significant money since starting. They reported losing tens of millions of dollars each year. They expect to keep losing money for a few more years. This funds their clinical trials. This is normal for companies at this stage. They invest heavily in drug trials. These trials can cost hundreds of millions over several years.

They haven't sold any approved products yet. So, no money comes in from drug sales. For the year ending December 31, 2025, they had no sales. They will likely need to raise more money in the future. They might sell more shares, borrow money, or form partnerships. This will keep operations going and fund drug development. This is especially true as ACR-368 and ACR-2316 move into more expensive trials.

As of June 30, 2025, the company's total value on the stock market was about $20.4 million. This makes them a relatively small company. Small companies often have higher stock price swings and more risk. This compares to larger, more established drug companies. They also had about 38.7 million shares of stock available to trade as of March 16, 2026.

Any Big Wins or Bumps in the Road?

Bumps to watch out for: Remember, they are a "clinical-stage" company. Their success depends entirely on their drugs getting approved. This includes ACR-368 and ACR-2316. Regulators like the FDA must approve them. This process is long, expensive, and uncertain. Success is not guaranteed. Clinical trials can fail at any phase. Drugs might not work well enough. They could also have unexpected side effects or safety issues. Even if a drug succeeds in trials, regulatory approval is not guaranteed. It can also be delayed. If they cannot get drugs approved, or raise enough money, it's a big problem. This could halt operations or even lead to bankruptcy.

The cancer treatment market is also very competitive. Many big drug companies and other biotechs develop similar treatments. Acrivon's ability to protect its unique ideas and inventions through patents is also key to its long-term success. They also have a limited operating history. They went public in October 2022. This makes predicting future performance harder. More established companies have more data. Less historical data means investors have less to review. It's harder to judge management's decisions or how well they run the company.

What the Future Might Hold

Acrivon's future truly depends on its drug candidates. ACR-368 and ACR-2316 must succeed. They also need to secure more funding. Good clinical trial results would be a big boost. Especially from the ongoing Phase 2 APPO study for ACR-368. If these drugs show promise and move closer to approval, it's a huge step. This means possibly advancing to Phase 3 trials or even asking regulators for approval. Developing and proving their AP3 platform is also important. It could help them expand their drug development beyond current candidates. But biotech is a high-risk, high-reward game. One trial outcome can drastically change the company's value and future.